Pharmacy, Health Sciences & Exercise Science

Carboplatin's Effect on Toxicity After Change in Dosing

Presenter Information

Allison Buida, Butler University

Document Type

Oral Presentation

Location

Indianapolis, IN

Subject Area

Pharmacy, Health Sciences & Exercise Science

Start Date

11-4-2014 8:30 AM

End Date

11-4-2014 10:00 AM

Description

Background: Carboplatin is used to treat many types of cancer due to its alkylating-like properties resulting in cross-linking and interference of DNA. Doses of carboplatin are based on a goal AUC and the patient's glomerular filtration rate (GFR). These factors are combined in the Calvert Formula to calculate a dose of carboplatin. The Gynecologic Oncology Group (GOG) recommends calculating the GFR via the Cockroft-Gault equation and limiting the maximum GFR to 125mL/min. Prior, guidance for the calculation of carboplatin doses was lacking, leading to variations in practice and possible increased toxicity for patients with very high calculated creatinine clearances.

Study objective: To determine if dosing recommendations from the GOG have resulted in decreased toxicity for patients being treated with carboplatin as either monotherapy or combination therapy for various gynecological cancers. The secondary objectives are to determine if guidelines are being followed and to describe any changes in carboplatin dosing.

Methods: A retrospective chart review involving patients receiving a minimum of one dose of carboplatin for the treatment of gynecological cancer at St. Vincent Hospital in Indianapolis, IN. Dates of treatment will be divided into two groups: the group prior to publication of GOG guidelines will received their first dose between July 2010 and October 2010, with the group after receiving dose(s) between July 2012 and October 2012. All information was gathered from patient charts and electronic health records. Patients who were pregnant, not treated for gynecological cancer, or who had no noted GFR will be excluded from the study. Data collected includes diagnosis, age, height, weight, serum creatinine, and pertinent past medical history. Additionally, select laboratory values and concurrent medications of note were recorded. Documented toxicities and dose delays of carboplatin were also be noted.

Results: To be presented at the Undergraduate Research Conference.

This document is currently not available here.

Share

COinS
 
Apr 11th, 8:30 AM Apr 11th, 10:00 AM

Carboplatin's Effect on Toxicity After Change in Dosing

Indianapolis, IN

Background: Carboplatin is used to treat many types of cancer due to its alkylating-like properties resulting in cross-linking and interference of DNA. Doses of carboplatin are based on a goal AUC and the patient's glomerular filtration rate (GFR). These factors are combined in the Calvert Formula to calculate a dose of carboplatin. The Gynecologic Oncology Group (GOG) recommends calculating the GFR via the Cockroft-Gault equation and limiting the maximum GFR to 125mL/min. Prior, guidance for the calculation of carboplatin doses was lacking, leading to variations in practice and possible increased toxicity for patients with very high calculated creatinine clearances.

Study objective: To determine if dosing recommendations from the GOG have resulted in decreased toxicity for patients being treated with carboplatin as either monotherapy or combination therapy for various gynecological cancers. The secondary objectives are to determine if guidelines are being followed and to describe any changes in carboplatin dosing.

Methods: A retrospective chart review involving patients receiving a minimum of one dose of carboplatin for the treatment of gynecological cancer at St. Vincent Hospital in Indianapolis, IN. Dates of treatment will be divided into two groups: the group prior to publication of GOG guidelines will received their first dose between July 2010 and October 2010, with the group after receiving dose(s) between July 2012 and October 2012. All information was gathered from patient charts and electronic health records. Patients who were pregnant, not treated for gynecological cancer, or who had no noted GFR will be excluded from the study. Data collected includes diagnosis, age, height, weight, serum creatinine, and pertinent past medical history. Additionally, select laboratory values and concurrent medications of note were recorded. Documented toxicities and dose delays of carboplatin were also be noted.

Results: To be presented at the Undergraduate Research Conference.